These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 35732329)
1. Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer. Stella S; Vitale SR; Massimino M; Motta G; Longhitano C; Lanzafame K; Martorana F; Fazzari C; Vecchio GM; Tirrò E; Inzerilli N; Carciotto R; Manzella L; Caruso M; Vigneri P Cancer Genomics Proteomics; 2022; 19(4):464-476. PubMed ID: 35732329 [TBL] [Abstract][Full Text] [Related]
2. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts. Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320 [TBL] [Abstract][Full Text] [Related]
3. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers. Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759 [TBL] [Abstract][Full Text] [Related]
4. In vitro effect of PIK3CA/mTOR inhibition in triple-negative breast cancer subtype cell lines. Kumar S; Bhattacharyya S; Das A; Singh G; Bal A Breast Dis; 2022; 41(1):241-247. PubMed ID: 35431224 [TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of metaplastic breast carcinoma via next-generation sequencing. Zhai J; Giannini G; Ewalt MD; Zhang EY; Invernizzi M; Niland J; Lai LL Hum Pathol; 2019 Apr; 86():85-92. PubMed ID: 30537493 [TBL] [Abstract][Full Text] [Related]
6. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Lehmann BD; Bauer JA; Schafer JM; Pendleton CS; Tang L; Johnson KC; Chen X; Balko JM; Gómez H; Arteaga CL; Mills GB; Sanders ME; Pietenpol JA Breast Cancer Res; 2014 Aug; 16(4):406. PubMed ID: 25103565 [TBL] [Abstract][Full Text] [Related]
7. Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities. Millis SZ; Jardim DL; Albacker L; Ross JS; Miller VA; Ali SM; Kurzrock R Cancer; 2019 Apr; 125(7):1185-1199. PubMed ID: 30582752 [TBL] [Abstract][Full Text] [Related]
8. Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors. Millis SZ; Ikeda S; Reddy S; Gatalica Z; Kurzrock R JAMA Oncol; 2016 Dec; 2(12):1565-1573. PubMed ID: 27388585 [TBL] [Abstract][Full Text] [Related]
9. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women. Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324 [TBL] [Abstract][Full Text] [Related]
10. The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas. Ng CKY; Piscuoglio S; Geyer FC; Burke KA; Pareja F; Eberle CA; Lim RS; Natrajan R; Riaz N; Mariani O; Norton L; Vincent-Salomon A; Wen YH; Weigelt B; Reis-Filho JS Clin Cancer Res; 2017 Jul; 23(14):3859-3870. PubMed ID: 28153863 [No Abstract] [Full Text] [Related]
11. Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer. Cossu-Rocca P; Orrù S; Muroni MR; Sanges F; Sotgiu G; Ena S; Pira G; Murgia L; Manca A; Uras MG; Sarobba MG; Urru S; De Miglio MR PLoS One; 2015; 10(11):e0141763. PubMed ID: 26540293 [TBL] [Abstract][Full Text] [Related]
12. Amato O; Buisseret L; Gebhart G; Plouznikoff N; Larsimont D; Awada A; Piccart M; Aftimos P Cold Spring Harb Mol Case Stud; 2023 Apr; 9(2):. PubMed ID: 36863843 [TBL] [Abstract][Full Text] [Related]
13. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients. Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828 [TBL] [Abstract][Full Text] [Related]
14. Genomic characterization reveals distinct mutational landscapes and therapeutic implications between different molecular subtypes of triple-negative breast cancer. Li RQ; Yan L; Zhang L; Ma HX; Wang HW; Bu P; Xi YF; Lian J Sci Rep; 2024 May; 14(1):12386. PubMed ID: 38811720 [TBL] [Abstract][Full Text] [Related]
15. Spectrum of PIK3CA/AKT mutations across molecular subtypes of triple-negative breast cancer. Kumar S; Bal A; Das A; Loriya I; Khare S; Bhattacharya S; Singh G Breast Cancer Res Treat; 2021 Jun; 187(3):625-633. PubMed ID: 33954864 [TBL] [Abstract][Full Text] [Related]
16. Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer. Browne IM; André F; Chandarlapaty S; Carey LA; Turner NC Lancet Oncol; 2024 Apr; 25(4):e139-e151. PubMed ID: 38547898 [TBL] [Abstract][Full Text] [Related]
17. Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses. Fumagalli C; Ranghiero A; Gandini S; Corso F; Taormina S; De Camilli E; Rappa A; Vacirca D; Viale G; Guerini-Rocco E; Barberis M Breast Cancer Res; 2020 Oct; 22(1):107. PubMed ID: 33059724 [TBL] [Abstract][Full Text] [Related]
18. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma. Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319 [TBL] [Abstract][Full Text] [Related]
19. Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer. Robles AJ; Cai S; Cichewicz RH; Mooberry SL Breast Cancer Res Treat; 2016 Jun; 157(3):475-88. PubMed ID: 27255535 [TBL] [Abstract][Full Text] [Related]
20. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer. Araki K; Miyoshi Y Breast Cancer; 2018 Jul; 25(4):392-401. PubMed ID: 29086897 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]